Vaccine Innovation: Challenges and Opportunities to Protect Health. Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines

Transcription

1 Vaccine Innovation: Challenges and Opportunities to Protect Health Julie Louise Gerberding, M.D., M.P.H President, Merck Vaccines

2 Protecting Health with Vaccines HEALTH IMPROVEMENT Population Impact Guidelines for Use Advocacy Access Consumer Engagement Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs

3 Developing just one new vaccine involves numerous discoveries in microbiology, chemistry, biochemistry, immunology and molecular biology, an average of 15 to 20 years of development, and extraordinary finances that can exceed the $800 million mark. IFPMA, 2010

4 Vaccine Pipeline: Prevention IFPMA, July 2009

5 Vaccine Pipeline: Non-infectious Diseases IFPMA, July 2009

6 Protecting Health with Vaccines Guidelines for Use Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs

7 1964 (6) Smallpox Polio Diphtheria Pertussis Tetanus Measles U.S Recommended Childhood Immunizations 1985 (7) 1995 (10) 2010 (16) Polio Diphtheria Pertussis Tetanus Measles Rubella Mumps Polio Diphtheria Pertussis Tetanus Measles Rubella Mumps Hib (infant) HepB Varicella Polio Diphtheria Pertussis Tetanus Measles Rubella Mumps Hib (infant) HepB HepA Varicella Pneumococcal Influenza Meningococcal Rotavirus HPV

8

9 Protecting Health with Vaccines Guidelines for Use Advocacy Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs

10 Estimated Vaccine Coverage among Children Months of Age, United States, Target MMR(1+) DTP / DTaP(3+) Polio (3+) Hep B (3+) PCV 7 (3+) Hib (3+) Varicella (1+) Source: USIS ( ), NHIS ( ) CDC, NCHS, and NIS (1994-December 2008), CDC, NIP, NCIRD and NCHS; No data from due to cancellation of USIS because of budget reductions.

11 Protecting Health with Vaccines Guidelines for Use Advocacy Access Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs

12 U.S. Pediatric Vaccines Recommended for Children 0-60 Years of Age: Doses Distributed by Funding Source Calendar Year 2007 Other including Private Sector 47% Section 317 Program 7% State Purchases 3% Vaccines for Children Program (VFC) 43% Source: Biologics Surveillance Data Represents a national summary of self-reported distribution data by the vaccine manufacturers. The data are an estimate of the annual national distribution and does not equal administration. Reported data may be incomplete and include possible over-reporting or under-reporting of distribution data and may not reflect all vaccines or manufacturers. Other represents all purchases not on CDC contracts, including private, health insurance, and government purchases through other mechanisms. Data do not include influenza vaccine doses. Updated July 17, 2008

13 We organized our numerous diverse insights about such barriers Identifying, registering and locating children for immunization Immunization session planning and management Immunization session execution and logistics Tracking children and work activities Accountability and training Awareness and demand

14 Protecting Health with Vaccines Guidelines for Use Advocacy Access Consumer Engagement Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs

15 Which concerns, if any, do you have about childhood vaccines? 2009 Weighted % It is painful for children to receive so many shots during one doctor s s visit. My child getting too many vaccines in one doctor s s visit. Vaccines causing fevers in my child. Children get too many vaccines in the first two years of life

16 Talking with Parents About Vaccines Audience: Healthcare providers During the Office Visit Take time to listen Solicit and welcome questions Keep the conversation going Use a mix of science and personal anecdotes Acknowledge benefits and risks Respect parents authority After the Office Visit Document parents questions/concerns Follow up a few days after the visit

17 Protecting Health with Vaccines HEALTH IMPROVEMENT Population Coverage Guidelines for Use Advocacy Access Consumer Engagement Evidence-based Value Research & Development Safety Efficacy Costeffectiveness Unmet Health Needs